{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:41:27Z","timestamp":1789072887305,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CIHR PS 178142"],"award-info":[{"award-number":["CIHR PS 178142"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"publisher","award":["RGPIN-2020-04437"],"award-info":[{"award-number":["RGPIN-2020-04437"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The International Journal of Biochemistry & Cell Biology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.biocel.2025.106826","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:51:01Z","timestamp":1751385061000},"page":"106826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Therapeutic potential of TIM-3 inhibition in cancer, viral infections, and autoimmune disorders"],"prefix":"10.1016","volume":"186","author":[{"given":"Ashira","family":"Manzoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3567-7279","authenticated-orcid":false,"given":"Khaled","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.biocel.2025.106826_bib1","doi-asserted-by":"crossref","first-page":"11464","DOI":"10.1021\/acs.jmedchem.3c00960","article-title":"Discovery of small-molecule TIM-3 inhibitors for acute myeloid leukemia using pharmacophore-based virtual screening","volume":"66","author":"Abdel-Rahman","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.biocel.2025.106826_bib4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jamaneurol.2014.395","article-title":"Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers","volume":"71","author":"Alvermann","year":"2014","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.biocel.2025.106826_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/eji.200939842","article-title":"T-bet, a Th1 transcription factor regulates the expression of Tim-3","volume":"40","author":"Anderson","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.biocel.2025.106826_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/JCI160025","article-title":"mTOR regulates T cell exhaustion and PD-1\u2013targeted Immunotherapy response during chronic viral infection","volume":"133","author":"Ando","year":"2023","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.biocel.2025.106826_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrrheum.2009.80","article-title":"Type 17 T helper cells\u2014origins, features and possible roles in rheumatic disease","volume":"5","author":"Annunziato","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"issue":"24","key":"10.1016\/j.biocel.2025.106826_bib8","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.3390\/cancers13246365","article-title":"Modulation of the Gal-9\/TIM-3 immune checkpoint with \u03b1-lactose. Does anomery of lactose matter","volume":"13","author":"Bailly","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biocel.2025.106826_bib9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.12688\/f1000research.13446.1","article-title":"Immune regulation by Tim-3","volume":"7","author":"Banerjee","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.biocel.2025.106826_bib10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood-2019-128178","article-title":"Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)","volume":"134","author":"Borate","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biocel.2025.106826_bib11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biocel.2025.106826_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biocel.2025.106826_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.immuni.2007.01.016","article-title":"T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface","volume":"26","author":"Cao","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.biocel.2025.106826_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110418","article-title":"T-cell immunoglobulin and mucin-domain containing-3 (TIM-3): Solving a key puzzle in autoimmune diseases","volume":"121","author":"Chen","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.biocel.2025.106826_bib15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid\u2013mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.biocel.2025.106826_bib16","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.00006-15","article-title":"Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression","volume":"89","author":"Clayton","year":"2015","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.biocel.2025.106826_bib17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/eji.1830240622","article-title":"B lymphocyte and macrophage expression of carcinoembryonic antigen-related adhesion molecules that serve as receptors for murine coronavirus","volume":"24","author":"Coutelier","year":"1994","journal-title":"Eur. J. Immunol."},{"issue":"8","key":"10.1016\/j.biocel.2025.106826_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.biocel.2025.106826_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058612","article-title":"Clonal expansions of CD8+ T cells with IL-10 secreting capacity occur during chronic Mycobacterium tuberculosis infection","volume":"8","author":"Cyktor","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.biocel.2025.106826_bib20","series-title":"BMJ Specialist Journals","article-title":"303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results","author":"Davar","year":"2020"},{"issue":"4","key":"10.1016\/j.biocel.2025.106826_bib21","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.0903059","article-title":"T cell\/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells","volume":"184","author":"DeKruyff","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.biocel.2025.106826_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.2504","article-title":"Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)","author":"Falchook","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35754-0","article-title":"High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3","volume":"8","author":"Gandhi","year":"2018","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.biocel.2025.106826_bib24","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","article-title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome","volume":"50","author":"Gayden","year":"2018","journal-title":"Nat. Genet."},{"issue":"18","key":"10.1016\/j.biocel.2025.106826_bib25","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1128\/JVI.00639-09","article-title":"Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells","volume":"83","author":"Golden-Mason","year":"2009","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.biocel.2025.106826_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nri1864","article-title":"CEACAM1: contact-dependent control of immunity","volume":"6","author":"Gray-Owen","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biocel.2025.106826_bib27","first-page":"191","article-title":"Engineering a CEACAM1 Variant with the Increased Binding Affinity to TIM-3 Receptor","volume":"27","author":"Hajihassan","year":"2023","journal-title":"Iran. Biomed. J."},{"issue":"8","key":"10.1016\/j.biocel.2025.106826_bib28","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1158\/1078-0432.CCR-20-4405","article-title":"Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia\/b study of LY3321367 with or without an anti-PD-L1 antibody","volume":"27","author":"Harding","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biocel.2025.106826_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.8_suppl.12","article-title":"A phase Ia\/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers","author":"Harding","year":"2019","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biocel.2025.106826_bib30","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.2147\/OTT.S170385","article-title":"TIM-3, a promising target for cancer immunotherapy","author":"He","year":"2018","journal-title":"OncoTargets Ther."},{"issue":"4","key":"10.1016\/j.biocel.2025.106826_bib31","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tube.2011.04.001","article-title":"T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis","volume":"91","author":"Henao-Tamayo","year":"2011","journal-title":"Tuberculosis"},{"issue":"26","key":"10.1016\/j.biocel.2025.106826_bib32","first-page":"6726","article-title":"CEACAM1+ myeloid cells control angiogenesis in inflammation","volume":"113","author":"Horst","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"7534","key":"10.1016\/j.biocel.2025.106826_bib33","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.biocel.2025.106826_bib34","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1084\/jem.20100687","article-title":"Tim3 binding to galectin-9 stimulates antimicrobial immunity","volume":"207","author":"Jayaraman","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biocel.2025.106826_bib35","article-title":"Tim-3 blockade elicits potent anti-multiple myeloma immunity of natural killer cells","volume":"12","author":"Jiang","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biocel.2025.106826_bib36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clim.2015.07.008","article-title":"Tim-3 promotes intestinal homeostasis in DSS colitis by inhibiting M1 polarization of macrophages","volume":"160","author":"Jiang","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.biocel.2025.106826_bib37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00403-016-1665-4","article-title":"Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) and TIM-3 ligands in peripheral blood from patients with systemic lupus erythematosus","volume":"308","author":"Jiao","year":"2016","journal-title":"Arch. Dermatol. Res."},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1600-065X.2012.01136.x","article-title":"Immune checkpoints in central nervous system autoimmunity","volume":"248","author":"Joller","year":"2012","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.biocel.2025.106826_bib39","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1084\/jem.20081398","article-title":"Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection","volume":"205","author":"Jones","year":"2008","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.biocel.2025.106826_bib40","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.4049\/jimmunol.166.11.6537","article-title":"Carcinoembryonic antigen-related cell adhesion molecule 1 on murine dendritic cells is a potent regulator of T cell stimulation","volume":"166","author":"Kammerer","year":"2001","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biocel.2025.106826_bib41","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1084\/jem.20062093","article-title":"Th2-driven, allergen-induced airway inflammation is reduced after treatment with anti\u2013Tim-3 antibody in vivo","volume":"204","author":"Kearley","year":"2007","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.biocel.2025.106826_bib42","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1111\/cas.15042","article-title":"TIM-3 in normal and malignant hematopoiesis: structure, function, and signaling pathways","volume":"112","author":"Kikushige","year":"2021","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.biocel.2025.106826_bib43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell stem Cell"},{"key":"10.1016\/j.biocel.2025.106826_bib44","series-title":"Seminars in immunology","article-title":"editors. CEACAM1 structure and function in immunity and its therapeutic implications","author":"Kim","year":"2019"},{"issue":"14","key":"10.1016\/j.biocel.2025.106826_bib45","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.3390\/cancers13143629","article-title":"Development of multidrug resistance in acute myeloid leukemia is associated with alterations of the LPHN1\/GAL-9\/TIM-3 signaling pathway","volume":"13","author":"Kocibalova","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.biocel.2025.106826_bib46","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients","volume":"22","author":"Kong","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biocel.2025.106826_bib47","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/jid.2009.362","article-title":"Molecular analysis of tumor-promoting CD8+ T cells in two-stage cutaneous chemical carcinogenesis","volume":"130","author":"Kwong","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.biocel.2025.106826_bib48","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2019.00835","article-title":"Blood levels of co-inhibitory-receptors: a biomarker of disease prognosis in multiple sclerosis","volume":"10","author":"Lavon","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biocel.2025.106826_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.05297-11","article-title":"Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways","author":"Lee","year":"2011","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.biocel.2025.106826_bib50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clim.2009.09.012","article-title":"Involvement of T cell Ig Mucin-3 (Tim-3) in the negative regulation of inflammatory bowel disease","volume":"134","author":"Li","year":"2010","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.biocel.2025.106826_bib51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2009.03.041","article-title":"Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner","volume":"283","author":"Lima","year":"2009","journal-title":"Cancer Lett."},{"issue":"13_ement","key":"10.1016\/j.biocel.2025.106826_bib52","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1158\/1538-7445.AM2018-5629","article-title":"Preclinical characterization of Sym023 a human anti-TIM3 antibody with a novel mechanism of action","volume":"78","author":"Lindsted","year":"2018","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biocel.2025.106826_bib53","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clim.2010.07.012","article-title":"Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity","volume":"137","author":"Liu","year":"2010","journal-title":"Clin. Immunol."},{"issue":"32","key":"10.1016\/j.biocel.2025.106826_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202305089","article-title":"Arf1 ablation in colorectal cancer cells activates a super signal complex in DC to enhance anti-tumor immunity","volume":"10","author":"Ma","year":"2023","journal-title":"Adv. Sci."},{"issue":"722","key":"10.1016\/j.biocel.2025.106826_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg6752","article-title":"Identification of a small-molecule Tim-3 inhibitor to potentiate T cell\u2013mediated antitumor immunotherapy in preclinical mouse models","volume":"15","author":"Ma","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biocel.2025.106826_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz253.028","article-title":"Phase (Ph) II study of MBG453+ spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti\u2013PD-1\/L1 therapy","volume":"30","author":"Mach","year":"2019","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.biocel.2025.106826_bib57","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1172\/JCI43127","article-title":"Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity","volume":"120","author":"McMahan","year":"2010","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.biocel.2025.106826_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092371","article-title":"Peripheral blood TIM-3 positive NK and CD8+ T cells throughout pregnancy: TIM-3\/galectin-9 interaction and its possible role during pregnancy","volume":"9","author":"Meggyes","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","article-title":"TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer","volume":"33","author":"de Mingo Pulido","year":"2018","journal-title":"Cancer Cell"},{"issue":"6871","key":"10.1016\/j.biocel.2025.106826_bib60","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"issue":"69","key":"10.1016\/j.biocel.2025.106826_bib61","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0959-8049(16)32903-3","article-title":"Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody","volume":"1","author":"Murtaza","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.biocel.2025.106826_bib62","first-page":"2565","article-title":"TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells","volume":"110","author":"Nakae","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"4","key":"10.1016\/j.biocel.2025.106826_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001030","article-title":"HTLV-1 tax specific CD8+ T cells express low levels of Tim-3 in HTLV-1 infection: implications for progression to neurological complications","volume":"5","author":"Ndhlovu","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.biocel.2025.106826_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111186","article-title":"Novel immune checkpoint targets: a promising therapy for cancer treatments","volume":"126","author":"Patwekar","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.biocel.2025.106826_bib65","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.7314\/APJCP.2013.14.6.3897","article-title":"Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer","volume":"14","author":"Piao","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.biocel.2025.106826_bib66","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/bloodadvances.2018028340","article-title":"Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma","volume":"3","author":"Polprasert","year":"2019","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.biocel.2025.106826_bib67","doi-asserted-by":"crossref","first-page":"14757","DOI":"10.1021\/acs.jmedchem.1c01336","article-title":"Fragment-based discovery of small molecules bound to T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3)","volume":"64","author":"Rietz","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.biocel.2025.106826_bib68","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni988","article-title":"Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance","volume":"4","author":"Sabatos","year":"2003","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.biocel.2025.106826_bib69","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41390-021-01588-2","article-title":"Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes","volume":"90","author":"Sag","year":"2021","journal-title":"Pediatr. Res."},{"issue":"11","key":"10.1016\/j.biocel.2025.106826_bib70","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","article-title":"TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors","volume":"72","author":"Sauer","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biocel.2025.106826_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108155","article-title":"Functional role of galectin-9 in directing human innate immune reactions to Gram-negative bacteria and T cell apoptosis","volume":"100","author":"Schlichtner","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.biocel.2025.106826_bib72","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.4049\/jimmunol.1901481","article-title":"Galectin-9 and VISTA expression define terminally exhausted T cells in HIV-1 infection","volume":"204","author":"Shahbaz","year":"2020","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biocel.2025.106826_bib73","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clim.2012.09.001","article-title":"Dysregulated Tim-3 expression and its correlation with imbalanced CD4 helper T cell function in ulcerative colitis","volume":"145","author":"Shi","year":"2012","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.biocel.2025.106826_bib74","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","article-title":"Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade","volume":"2","author":"da Silva","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biocel.2025.106826_bib75","series-title":"Regulation of TIM-3 by Phosphatidylserine","author":"Smith","year":"2021"},{"issue":"17","key":"10.1016\/j.biocel.2025.106826_bib76","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1042\/BCJ20210425","article-title":"Phosphatidylserine binding directly regulates TIM-3 function","volume":"478","author":"Smith","year":"2021","journal-title":"Biochem. J."},{"key":"10.1016\/j.biocel.2025.106826_bib77","first-page":"1","article-title":"H-x, et al. Increased Tim-3 expression on peripheral T lymphocyte subsets and association with higher disease activity in systemic lupus erythematosus","volume":"10","author":"Song L-j","year":"2015","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.biocel.2025.106826_bib78","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1007\/s10753-017-0577-6","article-title":"Tim3+ Foxp3+ Treg cells are potent inhibitors of effector T cells and are suppressed in rheumatoid arthritis","volume":"40","author":"Sun","year":"2017","journal-title":"Inflammation"},{"issue":"5","key":"10.1016\/j.biocel.2025.106826_bib79","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/0008-5472.CAN-19-2332","article-title":"Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling","volume":"80","author":"Tan","year":"2020","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.biocel.2025.106826_bib80","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1074\/jbc.272.10.6416","article-title":"Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease","volume":"272","author":"T\u00fcreci","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib81","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaci.2020.09.007","article-title":"Elevated plasma sTIM-3 levels in patients with severe COVID-19","volume":"147","author":"Ueland","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.biocel.2025.106826_bib82","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.4049\/jimmunol.1300711","article-title":"Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung","volume":"192","author":"Vega-Carrascal","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.biocel.2025.106826_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2023.107852","article-title":"N-glycosylation reinforces interaction of immune checkpoint TIM-3 with a small molecule ligand","volume":"104","author":"Vergoten","year":"2023","journal-title":"Comput. Biol. Chem."},{"issue":"13","key":"10.1016\/j.biocel.2025.106826_bib84","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1158\/1538-7445.AM2018-3825","article-title":"INCAGN02390, a novel antagonist antibody that targets the co-inhibitory receptor TIM-3","volume":"78","author":"Waight","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib85","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-3083.2007.02038.x","article-title":"Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients","volume":"67","author":"Wang","year":"2008","journal-title":"Scand. J. Immunol."},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","article-title":"The immunology of rheumatoid arthritis","volume":"22","author":"Weyand","year":"2021","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.biocel.2025.106826_bib87","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biocel.2025.106826_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115583","article-title":"Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy","volume":"212","author":"Wu","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.biocel.2025.106826_bib89","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.intimp.2015.09.017","article-title":"Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma","volume":"29","author":"Xu","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.biocel.2025.106826_bib90","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biocel.2025.106826_bib91","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3389\/fimmu.2019.01594","article-title":"The Tim-3-Galectin-9 pathway and its regulatory mechanisms in human breast cancer","volume":"10","author":"Yasinska","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib92","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/16078454.2020.1738097","article-title":"Pre-transplant sTIM-3 levels may have a predictive impact on transplant outcome in acute leukemia patients","volume":"25","author":"Yegin","year":"2020","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib93","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.biocel.2025.106826_bib94","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)+ azacitidine in higher risk MDS and CMML-2","volume":"19","author":"Zeidan","year":"2023","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.biocel.2025.106826_bib95","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1744921","article-title":"Identification and characterization of M6903, an antagonistic anti\u2013TIM-3 monoclonal antibody","volume":"9","author":"Zhang","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biocel.2025.106826_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107458","article-title":"The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells","author":"Zhang","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"13_ement","key":"10.1016\/j.biocel.2025.106826_bib97","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1158\/1538-7445.AM2017-2628","article-title":"BGB-A425: a humanized anti-human Tim-3 antibody that exhibits strong immune cell activation","volume":"77","author":"Zhang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.biocel.2025.106826_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107933","article-title":"TIM-3: an update on immunotherapy","volume":"99","author":"Zhao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biocel.2025.106826_bib99","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00280-020-04167-0","article-title":"The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo","volume":"86","author":"Zhong","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.biocel.2025.106826_bib100","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."}],"container-title":["The International Journal of Biochemistry & Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272525000949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272525000949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:15:26Z","timestamp":1752711326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1357272525000949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":100,"alternative-id":["S1357272525000949"],"URL":"https:\/\/doi.org\/10.1016\/j.biocel.2025.106826","relation":{},"ISSN":["1357-2725"],"issn-type":[{"value":"1357-2725","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of TIM-3 inhibition in cancer, viral infections, and autoimmune disorders","name":"articletitle","label":"Article Title"},{"value":"The International Journal of Biochemistry & Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biocel.2025.106826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106826"}}